NDLI: Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.

Please wait, while we are loading the content...

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.

Content Provider	Semantic Scholar
Author	Vrdoljak, Eduard Boban, Marijo Omrčen, Tomislav Hrepić, Dario Fridl-Vidas, V. Bošković, Lidija
Copyright Year	2011
Abstract	Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m² day 1 and capecitabine 1000 mg/m² twice daily, days 1-14. Combination chemotherapy was administered for a maximum six cycles, single-agent capecitabine could be continued until progressive disease or unacceptable toxicity. Thirty patients were included, objective response rate was 65.5%. After a median follow-up of 18.5 months, median time to progression was 8.5 months and median overall survival was 29.8 months. The main adverse events were thrombocytopenia, pneumonitis and hemolytic uremic syndrome. Our data suggest that first-line capecitabine and MMC has good antitumor activity in MBC, but is associated with MMC-specific toxicity.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://www.elis.sk/download_file.php?product_id=2201&session_id=09c0b46233257725bb42bd3a983e8b7b
PubMed reference number	21275468v1
Volume Number	58
Issue Number	2
Journal	Neoplasma
Language	English
Access Restriction	Open
Subject Keyword	Adverse event Adverse reaction to drug Anthracyclines Carcinoma breast stage IV Follow-Up Report Hemolytic-Uremic Syndrome Mammary Neoplasms Mitomycin One Thousand Overall Survival Patients Pharmaceutical Adjuvants Pneumonia Taxanes Thrombocytopenia Xenograft procedure capecitabine mecarzole
Content Type	Text
Resource Type	Article

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in